Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

Faivre-Finn C., Spigel D., Senan S., Langer C., Perez B., Özgüroğlu M., ...Daha Fazla

Lung cancer (Amsterdam, Netherlands), cilt.151, ss.30-38, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 151
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.lungcan.2020.11.024
  • Dergi Adı: Lung cancer (Amsterdam, Netherlands)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.30-38
  • Anahtar Kelimeler: Chemoradiotherapy, Chemotherapy, Radiotherapy, Non-small-cell lung cancer, Immunotherapy, CELL LUNG-CANCER, PD-L1 EXPRESSION, CHEMOTHERAPY, DOCETAXEL, RADIOTHERAPY, CONCURRENT, CISPLATIN, NIVOLUMAB, BIOMARKER, BLOCKADE
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Introduction: The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based chemoradiotherapy (CRT). A range of CT and RT regimens were permitted, and used, in the trial. We report post-hoc, exploratory analyses of clinical outcomes from PACIFIC according to CRT-related variables.